You are about to leave jnjmedicaldevices.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Features & Benefits
-
High HA (Hyaluronic Acid) Concentration
High concentration maximizes the potential for impacting osteoarthritic cell function and restoring native HA production. MONOVISC is delivered as a 4 mL injection with an HA concentration 88mg per injection.1
-
Supporting Documentation
Resources
MONOVISC® White Paper
My Visco™ Patient Brochure
MONOVISC® Patient Brochure
References
1. Mitek Sports Medicine. “Clinical Efficacy and Safety of MONOVISC® High Molecular Weight Hyaluronan” June 2014. DSUS/MTK/0714/-232
Indication Statement
Indications for Use
Monovisc™ is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).
MONOVISC® Hyaluronan may enhance the viscoelastic properties of synovial fluid to relieve pain and increase mobility
MONOVISC® is manufactured by and is a registered trademark of Anika Therapeutics, Inc.
All medical devices have associated risks. Please refer to the package insert and other labeling for a complete list of indications, contraindications, precautions and warnings. For further information on DePuy Synthes Products, please contact your local DePuy Synthes Representative.
094212-180628
© DePuy Synthes 2020. All Rights Reserved. This site is published by the DePuy Synthes Companies, which are solely responsible for its content. This site is governed solely by applicable U.S. laws and governmental regulations. This site is for visitors from the United States. The third party trademarks used herein are the trademarks of their respective owners.